

Dear editor,

Thank you very much for your response and reviewers' insightful comments on our manuscript (89389). We provide this letter to explain, point by point, the details of our revisions in the manuscript and our responses to the reviewers' comments as follows.

We hope that you can consider our revised manuscript for publishing in *World Journal of Gastrointestinal Oncology*. And your favorable consideration would be greatly appreciated.

Thanks for your continued attention.

Sincerely Yours,

Wen-Ming Chen

Department of oncology

Jining First People's Hospital, No.6, Jiankang Road, Jining City, 272011, Shandong Province, China.

---

**The point-by-point responses to reviewers are listed below:**

**Responses to Reviewer 1:**

**The reviewer's comment:** The reviewer's comment: It was a specific study. Although I have no experience on the subject, I gained new information as I read. I believe that it will contribute to the literature and be useful to the reader. Briefly; There are differences in the LncRNA software in the article (lncrna ? etc...). It will be more understandable if they are all in the same format (LncRNA). Many abbreviations have

been used without open software. I especially recommend that the words mentioned in the text be used with their abbreviations at the first mention.

**Response:** Thanks for your comments and your helpful suggestion. According to your advice, I have standardized and unified the writing of lncRNA in the manuscript as "lncRNA", and the plural form is "lncRNAs". But when this word is in the first word of the paragraph, the first letter is capitalized as "LncRNA". Many abbreviations in the manuscript are specific nouns in the corresponding fields, and I am sorry that I did not find their full names, such as: GATA6-AS1, HOXC-AS3, YBX1, HOXA11-AS, PRSS8, KLF2, LOXL1-AS1, FEZF1-AS1, LINC00022; But when I looked at the literature, I found that when these words first appear in an article, they can also be expressed as abbreviations.

**Science editor:**

**1) Specific comments:** (1) Please provide the Biostatistics statement. (2) Please provide the Institutional review board statement. (3) Please provide the Informed consent statement. (4) Please provide the Language certificate. The English-language grammatical presentation needs to be improved to a certain extent. There are many errors in grammar and format, throughout the entire manuscript. Before final acceptance, the authors must provide the English Language Certificate issued by a professional English language editing company. Please visit the following website for the professional English language editing companies we recommend: <https://www.wjgnet.com/bpg/gerinfo/240>.

**Response:** Thank you for your remind. We have already uploaded (1) as 89389-Biostatistics Review Certificate, (4) as 89389-Non-Native Speakers of English Editing Certificate; And the manuscript has been professionally polished for grammar and formatting. Supplementary instruction: This manuscript does not involve human studies and animal experiments.

**2) Specific comments:** (5) Please provide the Figures cited in the original manuscript in the form of PPT. All text can be edited, including A, B, arrows, etc. With respect to the reference to the Figure, please verify if it is an original image created for the manuscript, if not, please provide the source of the picture and the proof that the

Figure has been authorized by the previous publisher or copyright owner to allow it to be redistributed. All legends are incorrectly formatted and require a general title and explanation for each figure. Such as Figure 1 title. A: ; B: ; C: . (6) Please obtain permission for the use of picture(s). If an author of a submission is re-using a figure or figures published elsewhere, or that is copyrighted, the author must provide documentation that the previous publisher or copyright holder has given permission for the figure to be re-published, and correctly indicate the reference source and copyrights. For example, “Figure 1 Histopathological examination by hematoxylin-eosin staining (200 ×). A: Control group; B: Model group; C: Pioglitazone hydrochloride group; D: Chinese herbal medicine group. Citation: Yang JM, Sun Y, Wang M, Zhang XL, Zhang SJ, Gao YS, Chen L, Wu MY, Zhou L, Zhou YM, Wang Y, Zheng FJ, Li YH. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(34): 5105-5119. Copyright © 2019 The Author(s) 2019. Published by Baishideng Publishing Group Inc[6]”. And please cite the reference source in the references list. If the author fails to properly cite the published or copyrighted picture(s) or table(s) as described above, he/she will be subject to withdrawal of the article from BPG publications and may even be held liable.

**Response:** Thanks for your reminder. All Figures in this manuscript are derived from our original data, none of them have been published before. In addition, I have made all the Figures in the manuscript into a PPT according to your requirements and uploaded it as 89389-Image File.

**3) Specific comments:** (7) Please don't include any \*, #, §, ¶, @.... in your manuscript; Please use superscript numbers for illustration; and for statistical significance, please use superscript letters. Statistical significance is expressed as  $aP < 0.05$ ,  $bP < 0.01$  ( $P > 0.05$  usually does not need to be denoted). If there are other series of P values,  $cP < 0.05$  and  $dP < 0.01$  are used, and a third series of P values is expressed as  $eP < 0.05$  and  $fP < 0.01$ .

**Response:** Thank you for your remind. I have removed special symbols such as "#"

and "\*" from the manuscript.

**4)Specific comments:** (8) The “Article Highlights” section is missing. Please add the “Article Highlights” section at the end of the main text (and directly before the References).

**Response:** Thank you for your remind. I have added “Article Highlights” at the end of the manuscript body, before the references,please check.

**5)Specific comments:** (9) Please provide all fund documents.

**Response:** Thank you for your remind. I have added the fund information before “Article Highlights” in the manuscript, and uploaded the materials.

**6)Specific comments:** (10) Please provide the PubMed numbers and DOI citation numbers to the reference list and list all authors of the references. If there is no PMID or DOI, please provide the website address.

**Response:** Thank you for your remind. I have added PMID and DOI to each reference in the manuscript.

**Company editor-in-chief:** I recommend the manuscript to be published in the World Journal of Gastrointestinal Oncology. When revising the manuscript, it is recommended that the author supplement and improve the highlights of the latest cutting-edge research results, thereby further improving the content of the manuscript. To this end, authors are advised to apply PubMed, or a new tool, the RCA, of which data source is PubMed. RCA is a unique artificial intelligence system for citation index evaluation of medical science and life science literature. In it, upon obtaining search results from the keywords entered by the author, "Impact Index Per Article" under "Ranked by" should be selected to find the latest highlight articles, which can then be used to further improve an article under preparation/peer-review/revision. Please visit our RCA database for more information at: <https://www.referencecitationanalysis.com/>, or visit PubMed at: <https://pubmed.ncbi.nlm.nih.gov/>.

**Response:** Thank you very much for your comments and suggestions,your recognition deeply inspires me. By reviewing the literature in PubMed, I have added “Article Highlights” at the end of the manuscript body, before the references.

